Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Debt (2019 - 2025)

Akebia Therapeutics (AKBA) has disclosed Non-Current Debt for 7 consecutive years, with $48.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt rose 24.7% to $48.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.2 million through Dec 2025, up 24.7% year-over-year, with the annual reading at $48.2 million for FY2025, 24.7% up from the prior year.
  • Non-Current Debt for Q4 2025 was $48.2 million at Akebia Therapeutics, up from $47.6 million in the prior quarter.
  • The five-year high for Non-Current Debt was $97.2 million in Q3 2021, with the low at $17.2 million in Q4 2023.
  • Average Non-Current Debt over 5 years is $47.3 million, with a median of $38.5 million recorded in 2024.
  • The sharpest move saw Non-Current Debt crashed 49.58% in 2023, then soared 125.18% in 2024.
  • Over 5 years, Non-Current Debt stood at $97.2 million in 2021, then tumbled by 64.95% to $34.1 million in 2022, then plummeted by 49.58% to $17.2 million in 2023, then soared by 125.18% to $38.7 million in 2024, then grew by 24.7% to $48.2 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $48.2 million, $47.6 million, and $47.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.